Seelos therapeutics doses first patients in an ethnobridging study with sls-002 (intranasal racemic ketamine)

-seelos is conducting a phase i ethnobridging study in healthy japanese and non-asian subjects to evaluate the safety and pharmacokinetic profiles of sls-002. new york , feb. 6, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has dosed the first patients in an ethnobridging study in healthy adult japanese and non-asian subjects to compare the safety and pharmacokinetic profiles of sls-002 (intranasal racemic ketamine).
SEEL Ratings Summary
SEEL Quant Ranking